In the subanalysis including only IBD patients (3706 patients contributing 10,332 person-years of follow-up), the pooled incidence of new or recurrent cancer in anti-TNFα was 48.5 per 1000 p-y without statistical difference with the other group of patients, even if the value was higher compared to the other groups (no therapy 35.7 per 1000 p-y and IMM 37.9 per 1000 p-y, p > 0.30). Here, TNF is linked to inflammatory bowel disease.